Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab

Overview of attention for article published in Journal of Hematology & Oncology, October 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

patent: 4 patents

Citations

dimensions_citation: 141 Dimensions

Readers on

mendeley: 124 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 4 patents that reference this research output.

TRISPECIFIC ANTIBODY TARGETING CD79b, CD20, AND CD3

Application WO-2022200443-A1

World Intellectual Property Organisation (WIPO)

TRISPECIFIC MOLECULE COMBINING SPECIFIC TUMOR TARGETING AND LOCAL IMMUNE CHECKPOINT…

Grant EP-3374394-B1

European Patent Office

Cytotoxicity-inducing therapeutic agent

Grant US-11066483-B2

United States of America

COMPOSITIONS AND METHODS FOR TREATING DIFFUSE LARGE B CELL LYMPHOMA

Application WO-2019075366-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.